NCT00388947

Brief Summary

This registry was observational (only collected information typically noted by the surgeon when their patients were routinely seen); there was no change to the care the patient received as a result of being part of the registry). Data collection focused on the surgical outcomes of AMS prolapse products.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,543

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2006

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2006

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 16, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 17, 2006

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
2.6 years until next milestone

Results Posted

Study results publicly available

November 20, 2012

Completed
Last Updated

August 11, 2016

Status Verified

July 1, 2016

Enrollment Period

3.7 years

First QC Date

October 16, 2006

Results QC Date

August 3, 2012

Last Update Submit

July 11, 2016

Conditions

Keywords

vaginal prolapsecystocelerectoceleenteroceleapical prolapsevaginal vault prolapse

Outcome Measures

Primary Outcomes (1)

  • Count of Patients With at Least One Adverse Event Related to Any AMS Prolapse Device

    up to 2-years post-implant

Secondary Outcomes (1)

  • Prolapse Efficacy Success Rate

    24 months

Study Arms (1)

1

AMS Prolapse Product (AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family)

Device: AMS Prolapse Product

Interventions

AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family

Also known as: Apogee, Straight-In, Perigee, Elevate anterior, Elevate Posterior
1

Eligibility Criteria

Age21 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Female subjects greater than or equal to 21 years of age with genital prolapse who undergo surgical reconstruction of the pelvic floor using an AMS Prolapse Repair device.

You may qualify if:

  • Female at least 21 years old
  • Has pelvic organ prolapse requiring surgical repair
  • Receives at least one of the AMS Prolapse Repair devices in the treatment of their pelvic organ prolapse

You may not qualify if:

  • Is contraindicated for an AMS Prolapse Repair per the product's Instruction for Use.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samuel Zylstra, MD

Whitinsville, Massachusetts, 01588, United States

Location

MeSH Terms

Conditions

Uterine ProlapseCystoceleRectoceleHerniaPelvic Organ Prolapse

Condition Hierarchy (Ancestors)

Uterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesProlapsePathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsUrinary Bladder DiseasesUrologic DiseasesMale Urogenital DiseasesRectal DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Results Point of Contact

Title
Dr Samuel Zylstra
Organization
Whitinsville Medical Center

Study Officials

  • Samuel Zylstra, MD

    Whitinsville Medical Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 16, 2006

First Posted

October 17, 2006

Study Start

September 1, 2006

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

August 11, 2016

Results First Posted

November 20, 2012

Record last verified: 2016-07

Data Sharing

IPD Sharing
Will not share

Locations